{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=FIGO+Stage+III+Ovarian+Cancer&page=13",
    "query": {
      "condition": "FIGO Stage III Ovarian Cancer",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 348,
    "total_pages": 35,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=FIGO+Stage+III+Ovarian+Cancer&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=FIGO+Stage+III+Ovarian+Cancer&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T23:41:33.241Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01685255",
      "title": "A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Genitourinary (GU) Tumors"
      ],
      "interventions": [
        {
          "name": "Epacadostat",
          "type": "DRUG"
        },
        {
          "name": "tamoxifen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 83,
      "start_date": "2012-08",
      "completion_date": "2014-10-23",
      "has_results": false,
      "last_update_posted_date": "2019-03-11",
      "last_synced_at": "2026-10-14T23:41:33.241Z",
      "location_count": 17,
      "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 14 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Joliet",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01685255"
    },
    {
      "nct_id": "NCT01867086",
      "title": "Salvage Ovarian FANG™ Vaccine + Carboplatinum",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage III Ovarian Cancer",
        "Stage IV Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Vigil™ Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carboplatinum",
          "type": "DRUG"
        },
        {
          "name": "Carboplatinum and Taxol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Gradalis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2013-06",
      "completion_date": "2016-04-08",
      "has_results": true,
      "last_update_posted_date": "2018-06-19",
      "last_synced_at": "2026-10-14T23:41:33.241Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01867086"
    },
    {
      "nct_id": "NCT04794322",
      "title": "Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ovarian Neoplasms",
        "Ovarian Epithelial Carcinoma",
        "Fallopian Tube Neoplasms",
        "High Grade Ovarian Serous Adenocarcinoma",
        "Stage I Ovarian Cancer",
        "Stage II Ovarian Cancer",
        "Stage III Ovarian Cancer AJCC v8",
        "Stage IIIA Ovarian Cancer AJCC v8",
        "Stage IIIA1 Ovarian Cancer AJCC v8",
        "Stage IIIA2 Ovarian Cancer AJCC v8",
        "Stage IIIB Ovarian Cancer AJCC v8",
        "Stage IIIC Ovarian Cancer AJCC v8",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IVA Ovarian Cancer AJCC v8",
        "Stage IVB Ovarian Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Uterine lavage, or a wash of the womb",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Blood sample",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Pap smear",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "30 Years and older · Female only"
      },
      "enrollment_count": 250,
      "start_date": "2020-04-13",
      "completion_date": "2028-08-31",
      "has_results": false,
      "last_update_posted_date": "2025-09-16",
      "last_synced_at": "2026-10-14T23:41:33.241Z",
      "location_count": 6,
      "location_summary": "Little Rock, Arkansas • San Francisco, California • Annapolis, Maryland + 3 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Annapolis",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04794322"
    },
    {
      "nct_id": "NCT03602859",
      "title": "A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ovarian Neoplasms",
        "Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Niraparib",
          "type": "DRUG"
        },
        {
          "name": "Dostarlimab (TSR-042)",
          "type": "DRUG"
        },
        {
          "name": "Standard of care",
          "type": "DRUG"
        },
        {
          "name": "Dostarlimab-Placebo",
          "type": "DRUG"
        },
        {
          "name": "Niraparib-Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tesaro, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 1400,
      "start_date": "2018-10-11",
      "completion_date": "2029-04-30",
      "has_results": true,
      "last_update_posted_date": "2025-12-31",
      "last_synced_at": "2026-10-14T23:41:33.241Z",
      "location_count": 65,
      "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 55 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03602859"
    },
    {
      "nct_id": "NCT00045006",
      "title": "Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2001-07",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2013-05-30",
      "last_synced_at": "2026-10-14T23:41:33.241Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00045006"
    },
    {
      "nct_id": "NCT00082654",
      "title": "Study of the Emotional Needs of Caregivers of Stem Cell Transplantation Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer",
        "Chronic Myeloproliferative Disorders",
        "Gestational Trophoblastic Tumor",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Diseases",
        "Neuroblastoma",
        "Ovarian Cancer",
        "Psychosocial Effects of Cancer and Its Treatment",
        "Testicular Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "psychosocial assessment and care",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2002-03",
      "completion_date": "2004-10",
      "has_results": false,
      "last_update_posted_date": "2010-09-21",
      "last_synced_at": "2026-10-14T23:41:33.241Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00082654"
    },
    {
      "nct_id": "NCT00002717",
      "title": "Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Primary Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 324,
      "start_date": "1996-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-05-27",
      "last_synced_at": "2026-10-14T23:41:33.241Z",
      "location_count": 52,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 42 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002717"
    },
    {
      "nct_id": "NCT01138137",
      "title": "N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Carcinoma, Stage 3 or 4",
        "Epithelial Ovarian Carcinoma",
        "Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "N-acetylcysteine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 75 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2010-06",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2017-04-21",
      "last_synced_at": "2026-10-14T23:41:33.241Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01138137"
    },
    {
      "nct_id": "NCT00382811",
      "title": "OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Peritoneal Neoplasms",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "phenoxodiol",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MEI Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 142,
      "start_date": "2006-10",
      "completion_date": "2011-04",
      "has_results": false,
      "last_update_posted_date": "2016-07-18",
      "last_synced_at": "2026-10-14T23:41:33.241Z",
      "location_count": 37,
      "location_summary": "Tuscon, Arizona • Glendale, California • Los Angeles, California + 32 more",
      "locations": [
        {
          "city": "Tuscon",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00382811"
    },
    {
      "nct_id": "NCT00445965",
      "title": "Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Intraocular Melanoma",
        "Lung Cancer",
        "Melanoma (Skin)",
        "Metastatic Cancer",
        "Neuroblastoma",
        "Ovarian Cancer",
        "Retinoblastoma",
        "Sarcoma",
        "Small Intestine Cancer"
      ],
      "interventions": [
        {
          "name": "DNA analysis",
          "type": "GENETIC"
        },
        {
          "name": "immunologic technique",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "iodine I 131 monoclonal antibody 3F8",
          "type": "RADIATION"
        },
        {
          "name": "131I-3F8",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 78,
      "start_date": "2006-01",
      "completion_date": "2023-02-01",
      "has_results": true,
      "last_update_posted_date": "2024-04-04",
      "last_synced_at": "2026-10-14T23:41:33.241Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00445965"
    }
  ]
}